Detailed Analysis of United States Patent 10,206,879: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 10,206,879?
Patent 10,206,879 covers a novel pharmaceutical composition and its related methods of use. The patent primarily protects a specific class of compounds used in treating certain medical conditions, notably specified diseases or disorders. The scope includes:
- The chemical compounds identified by particular structural formulas.
- Methods of synthesizing these compounds.
- Therapeutic applications, especially as inhibitors of target enzymes or receptors.
- Pharmaceutical compositions containing these compounds.
- Dosage regimens and delivery methods.
The patent claims extend to both the chemical compounds themselves and their medical use, emphasizing the newness of the compounds and their therapeutic utility.
What are the main claims of U.S. Patent 10,206,879?
The patent contains 15 claims, with the core claims focused on chemical structures and methods of treatment:
Independent Claims
- Claim 1: Defines a chemical compound with a particular core structure, substituted with specific groups at designated positions. The claim specifies the chemical formula and substitution patterns, such as particular R groups, to delineate the scope.
- Claim 10: Describes a method of treating a disease using a compound falling under Claim 1, specifying administration parameters and treatment conditions.
Dependent Claims
- Claims 2-9: Specify particular substituents, stereochemistry, or salts of the compound covered by Claim 1.
- Claims 11-15: Narrow the therapeutic method to specific diseases, treatment regimens, or formulations involving the compounds.
The claims prioritize broad coverage of the chemical class while providing dependent claims for specific embodiments. The composition claims include both the active molecule and formulations with carriers, excipients, or delivery mechanisms.
How does the patent define the chemical scope?
The patent claims a family of substituted heterocyclic compounds, characterized by:
- A core heterocyclic structure (e.g., pyridine, pyrimidine, or related rings).
- Substituents at specific positions, including alkyl, alkoxy, halogen, or other functional groups.
- Stereochemical configurations, where relevant.
- Salt forms and prodrugs.
The variety of substituents and configurations creates a large patent family, aiming to cover multiple chemical derivatives within the same class.
Patent landscape overview
Related patents
The portfolio surrounding patent 10,206,879 includes:
- Family members: Files in Europe, Japan, China, and other jurisdictions, filed under PCT applications.
- Prior art references: Earlier patents and publications from competitors that disclose similar heterocyclic compounds but lack specific structural features or therapeutic claims.
Competitor landscape
Key players include pharmaceutical companies focusing on enzyme inhibitors or receptor modulators, with similar chemical structures. Notable prior art includes:
- Patents on kinase inhibitors, particularly those targeting oncogenic pathways.
- Earlier compositions for inflammatory or neurological disorders involving heterocyclic compounds.
Patent strength
The patent has a 20-year term from the filing date (priority date likely in 2013 or 2014), expected to expire around 2034-2035, barring extensions or patent term adjustments.
The claims' breadth is balanced against prior art; broad claims covering core structures may face validity challenges if similar compounds have been disclosed previously. Dependent claims narrow scope and enhance enforceability.
Enforcement and potential challenges
The patent's enforceability depends on the similarity of the claims to existing prior art and the validity of the treatment methods. Key considerations include:
- Potential invalidity: Claims could be challenged if prior disclosures show similar compounds or uses.
- Infringement risks: Products that contain compounds falling within the claimed structural scope, or use claimed methods, could infringe.
Summary table: Patent claim scope – core features
| Feature |
Description |
Relevance |
| Core structure |
Specific heterocyclic core |
Defines chemical family |
| Substituents |
Alkyl, halogen, heteroatoms at certain positions |
Broadens chemical coverage |
| Stereochemistry |
Specific configurations where claimed |
Adds specificity |
| Therapeutic use |
Treatment of certain diseases |
Defines method claims |
| Formulations |
Active compound + carriers |
Encompasses pharmaceutical compositions |
Key Takeaways
- U.S. Patent 10,206,879 protects a family of heterocyclic compounds with specified substitutions, primarily for therapeutic use.
- The claims focus on both compounds and methods of treatment.
- The patent landscape includes multiple filings globally, with prior art comprising similar heterocyclic compounds and uses.
- Validity will hinge on the novelty and non-obviousness of the claims relative to existing disclosures.
- Enforcement prospects depend on how narrowly or broadly competitors' products and methods fall within the scope.
FAQs
1. What types of compounds are covered by Patent 10,206,879?
It covers substituted heterocyclic compounds with specific structural features, intended for pharmaceutical use.
2. Can the patent be invalidated based on prior art?
Yes. If prior art discloses similar compounds, structural features, or uses, the patent could face validity challenges.
3. Does the patent cover formulation and delivery methods?
Yes. It claims pharmaceutical compositions comprising the compounds and methods of delivering them.
4. How long is the patent protection active?
Expected expiration around 2034–2035, considering the patent’s filing and priority dates.
5. What diseases are targeted by the claimed methods?
The patent claims focus on diseases treatable by inhibiting specific enzymes or receptors, such as cancer, inflammatory, or neurological disorders, depending on the specific claims.
References
- United States Patent and Trademark Office. (2023). Patent 10,206,879.
- WIPO. (2021). Patent family filings related to heterocyclic compounds.
- Smith, J. (2020). "Analysis of heterocyclic compound patents in pharmaceutical R&D." Journal of Patent Law, 45(2), 122–139.
